Prognosis
AstraZeneca’s Covid Antibody Drug Heads Into Advanced Trials
- Company received $486 million from U.S. for development
- Spotlight on antibodies after Trump took Regeneron cocktail
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
AstraZeneca Plc started late-stage trials for an antibody medicine against Covid-19 with a large investment from the U.S., after President Donald Trump credited a similar therapy with aiding his recovery.